DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
RPL554 is an investigational drug.
There have been 10 clinical trials for RPL554. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2015.
The most common disease conditions in clinical trials are Lung Diseases, Pulmonary Disease, Chronic Obstructive, and Lung Diseases, Obstructive. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and Cystic Fibrosis Trust.
There are seventy-four US patents protecting this investigational drug and eight hundred and sixty international patents.
Recent Clinical Trials for RPL554
|Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD||IQVIA||Phase 2|
|Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD||LGC Limited||Phase 2|
|Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD||Verona Pharma plc||Phase 2|
Top disease conditions for RPL554
Top clinical trial sponsors for RPL554
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|RPL554||Get Started Free||Inhalable pharmaceutical compositions||iCeutica Pty Ltd. (Iluka, WA, AU)||Get Started Free|
|RPL554||Get Started Free||Gene fusions and gene variants associated with cancer||LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)||Get Started Free|
|RPL554||Get Started Free||3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors||Chiesi Farmaceutici S.p.A. (Parma, IT)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|RPL554||Australia||AU2013227351||2032-02-28||Get Started Free|
|RPL554||Australia||AU2016202881||2032-02-28||Get Started Free|
|RPL554||Australia||AU2017213466||2032-02-28||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|